Table 4.
Treatmenta | |||||
---|---|---|---|---|---|
Item | CON | AGR | MECb | SEMc | P |
Initial shoulder height, cm | 96.9 | 96.7 | 96.8 | 0.74 | 0.99 |
Initial hip height, cm | 101.2 | 100.7 | 101.0 | 0.72 | 0.96 |
Final shoulder height, cm | 105.3 | 104.2 | 103.8 | 0.51 | 0.46 |
Final hip height, cm | 113.8 | 113.8 | 113.4 | 0.54 | 0.94 |
Shoulder growth, cm | 8.4 | 7.5 | 6.8 | 0.51 | 0.47 |
Hip growth, cm | 12.7 | 13.1 | 12.2 | 0.50 | 0.78 |
Initial BW: shoulder | 2.17 | 1.97 | 2.18 | 0.059 | 0.28 |
Final BW: shoulder | 2.91 | 3.00 | 3.03 | 0.044 | 0.52 |
Initial BW: hip height | 2.09 | 2.08 | 2.07 | 0.044 | 0.99 |
Final BW: hip height | 3.14 | 3.28 | 3.30 | 0.049 | 0.36 |
aCalves were developed for 72 d: 1) control (CON), fed grower diet exclusively; 2) aggressive (AGR), fed 2.0% of initial BW on an as-fed basis of grower diet at 0630 h and ad libitum finishing diet at 0930 h; 3) M. elsdenii culture (MEC), drenched with 50 mL of M. elsdenii (Lactipro Advance; MS Biotech, Inc., Wamego, KS) on day 0 of the trial, fed 2.0% of initial BW on an as-fed basis of grower diet at 0630 h and ad libitum finishing diet at 0930 h.
bCalves were dosed with no M. elsdenii or 50 mg of M. elsdenii (Lactipro; MS Biotech, Inc., Wamego, KS) on day 1 of the trial.
cPooled standard error of treatment means (n = 15 pens/treatment).
a–cRow means that do not have common superscripts differ (P < 0.05).
x–yRow means that do not have common superscripts tend to differ (0.05 < P ≤ 0.10).